Evogene Ltd. · NASDAQ:EVGN

Evogene — Investor Presentation (August 2019)

51 slides from Evogene's investor presentation, August 2019

  1. Slide 1: Evogene at a Glance

    Slide 1: Evogene at a Glance

    August, 2019 EVOGENE AT A GLANCE… Ofer Haviv, President & CEO

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation contains "forward-looking statements" relating to All written and oral forward-looking statements attributable to us or future events, and we may from time to time make other statements, persons acting on our behalf are expressly qualified in their entirety by

  3. Slide 3: Agenda

    Slide 3: Agenda

    AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 3

  4. Slide 4: What We Do

    Slide 4: What We Do

    WHAT WE DO… We revolutionize the product development …through the use of a unique Computational process in life-science based markets… Predictive Biology (CPB) platform 4

  5. Slide 5: Agenda

    Slide 5: Agenda

    AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 5

  6. Slide 6: The Challenge

    Slide 6: The Challenge

    THE CHALLENGE Product development common practice Product Successful Definition Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion Low probability of success Long time to market High development costs Limited ‘next generation’ products in pipelines 6

  7. Slide 7: The Desired Solution

    Slide 7: The Desired Solution

    THE DESIRED SOLUTION Candidates with the highest probability of success Product Definition Successful Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion • Increasing probability of success Successful • Reducing time to Product Launch market Candidate

  8. Slide 8: Evogene's Unique Product Development Approach

    Slide 8: Evogene's Unique Product Development Approach

    EVOGENE’S UNIQUE PRODUCT DEVELOPMENT APPROACH Product Definition Successful Product Launch Efficacy Stability Shelf-life Safety Candidates mainly addressing the first criterion The CPB platform • Increasing Tailored big data probability of Science Interconnected data hub success Analysis platforms S

  9. Slide 9: Prediction of Candidates for Life-Science Based Products

    Slide 9: Prediction of Candidates for Life-Science Based Products

    PREDICTION OF CANDIDATES FOR LIFE-SCIENCE BASED PRODUCTS Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Genetic Bacterial genes – toxins for insects Elements Essential genes – target for herbicides

  10. Slide 10: Agenda

    Slide 10: Agenda

    AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 10

  11. Slide 11: Targeted Markets

    Slide 11: Targeted Markets

    TARGETED MARKETS Biotechnology for life science industries Green - Agriculture Castor oil White- Industrial Ag-Biologicals • Industrial application • Ag-Chemicals • Polymers • Seeds • Enzymes Ag-Chemicals • Ag-Biologicals • Bacteria • Precision Ag • Livestock • Biomaterials Seed Traits • Energy Medi

  12. Slide 12: Agenda

    Slide 12: Agenda

    AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 12

  13. Slide 13: Corporate Structure & Activities

    Slide 13: Corporate Structure & Activities

    CORPORATE STRUCTURE & ACTIVITIES CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stabilit

  14. Slide 14: Corteva to Invest in Lavie Bio

    Slide 14: Corteva to Invest in Lavie Bio

    & CORTEVA N X gene Corteva Agriscience to Invest in Evogene’s Agriculture Biologicals Subsidiary, Lavie Bio Investment Includes Equity and Corteva’s Shares in Taxon Biosciences for Shares in Lavie Bio Wilmington, Del., USA and Rehovot, Israel — Aug. 7, 2019 — Corteva, Inc. (NYSE: CTVA), a leading pu

  15. Slide 15: Main Collaborations

    Slide 15: Main Collaborations

    MAIN COLLABORATIONS CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil CASA 15

  16. Slide 16: Milestone Roadmap

    Slide 16: Milestone Roadmap

    MILESTONE ROADMAP Enter new collaboration agreement Reach ‘Lead’ in herbicide program Enter pre-clinical trials in 2 additional Complete first pre-clinical study in programs; positive results in at least oncology one study Complete two cannabis growth cycles Demonstrate first desired cannabis trait

  17. Slide 17: Agenda

    Slide 17: Agenda

    AGENDA What we Our Target Corporate Summary Annex I: do… technology - markets structure & subsidiary the CPB activities overview platform Annex II: financial fundamentals 17

  18. Slide 18: Evogene at a Glance Summary

    Slide 18: Evogene at a Glance Summary

    EVOGENE AT A GLANCE… SUMMARY WHAT WE DO CORPORATE STRUCTURE We revolutionize the product development process in life-science based Evogene and the CPB platform markets through the use of a unique Computational Predictive Biology at the heart of a group of (CPB) platform. subsidiaries, each focused i

  19. Slide 19: Evogene at a Glance

    Slide 19: Evogene at a Glance

    August, 2019 EVOGENE AT A GLANCE… Ofer Haviv, President & CEO Contact: ir@evogene.com T: +972 8 931 1963

  20. Slide 20: Annex I: Subsidiary Overview

    Slide 20: Annex I: Subsidiary Overview

    Annex I: Subsidiary Overview 20

  21. Slide 21: Corporate Structure

    Slide 21: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  22. Slide 22: AgPlenus (Ag-Chemicals) Mission & Products

    Slide 22: AgPlenus (Ag-Chemicals) Mission & Products

    AGPLENUS (AG-CHEMICALS) MISSION & PRODUCTS MISSION Design effective and sustainable crop protection products by leveraging predictive biology Main Products under development Herbicides –Market size: $25B* (2018), growing market need for novel herbicides with improved safety profile and solution for

  23. Slide 23: Business Model: Delivering De-risked Lead Candidates

    Slide 23: Business Model: Delivering De-risked Lead Candidates

    BUSINESS MODEL Delivering de-risked lead candidates Lead Continued development & Discovery Optimization regulation AgPlenus strategic focus Target Hit Lead Optimized Lead Starting point for • Indication for • Commercial-level • Commercial-level commercial-level commercial-level efficacy efficacy eff

  24. Slide 24: AgPlenus (Ag-Chemicals) - Pipeline

    Slide 24: AgPlenus (Ag-Chemicals) - Pipeline

    AGPLENUS (AG-CHEMICALS) - PIPELINE Continued Discovery Lead Optimization development Target Hit Lead Optimized lead Final Novel MoA/SoA product Herbicides Novel model of action (non-selective/selective) 10 product candidates Insecticides Novel site of action broad spectrum 5 targets/sites AI optimiz

  25. Slide 25: Corporate Structure

    Slide 25: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  26. Slide 26: Lavie Bio (Ag-Biologicals) Mission & Products

    Slide 26: Lavie Bio (Ag-Biologicals) Mission & Products

    LAVIE BIO (AG-BIOLOGICALS) MISSION & PRODUCTS MISSION Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products Products under development: Bio-Stimulant – Market size: $2B* (2016), Microbial based targeting yield improvement in row crops su

  27. Slide 27: Business Model

    Slide 27: Business Model

    BUSINESS MODEL Pre. Early Development Development Discovery Development Stage 1 Stage 2 Commercializatio n Fragmented Distribution markets A channels Consolidated markets B Partner Model A – Direct Market Access Model B – Market Access via partner Co-development of corn bio-stimulants with Corteva 2

  28. Slide 28: Lavie Bio (Ag-Biologicals) - Pipeline

    Slide 28: Lavie Bio (Ag-Biologicals) - Pipeline

    LAVIE BIO (AG-BIOLOGICALS) - PIPELINE Commerciali Product program Application Discovery Early Dev. Dev.stage 1 Dev. stage 2 Product zation Bio Stimulants Yield improvement Seed Corn under normal treatment & drought Yield improvement Seed Wheat under normal treatment & drought Bio Pesticides Protect

  29. Slide 29: Corporate Structure

    Slide 29: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  30. Slide 30: Ag Seeds - Mission & Products

    Slide 30: Ag Seeds - Mission & Products

    AG SEEDS - MISSION & PRODUCTS MISSION Bring to market top-quality seeds with high-value traits, under the “Triple S” Concept – Safe, Secure and Sustainable food Products under development mainly via (i) GMO and (ii) Genome Editing : Insect control traits- Lepidoptera, Coleoptera, Hemiptera Yield and

  31. Slide 31: Insect Control

    Slide 31: Insect Control

    INSECT CONTROL Discover & develop novel proteins conferring resistance to key insects through new modes of action Diverse trait portfolio with novel Mode of Action ! 31

  32. Slide 32: Insect Control - Example

    Slide 32: Insect Control - Example

    INSECT CONTROL- EXAMPLE Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments WT Exp. 1 Exp. 2 Exp. 3 100 100 100 90 90 90 80 80 80 70 70 70 P = 0.0278 P = 0.0068 P = 0.0001 Survival (%) Survival (%) Survival (%) 60 60 60 EV040030208 50 50 50 40 40 40 30 30 30

  33. Slide 33: Yield and Environmental Stress Product Candidates

    Slide 33: Yield and Environmental Stress Product Candidates

    YIELD AND ENVIRONMENTAL STRESS PRODUCT CANDIDATES* 18m-24m 4-6 year 2-4 year 1-2 years 1-2 years Phase 1 Phase 2 (Early Phase 3 (Adv. Crop Trait Partner Discovery Dev & Phase IV (POC) Development) Product Regulation) (Pre -Launch) Corn Yield Drought Nitrogen use efficiency Soybean Yield Drought *Tim

  34. Slide 34: Yield and Environmental Stress Collaboration Example: Bayer (Monsanto)

    Slide 34: Yield and Environmental Stress Collaboration Example: Bayer (Monsanto)

    YIELD AND ENVIRONMENTAL STRESS COLLABORATION EXAMPLE BAYER (MONSANTO)  Collaboration period - 10 years  Key terms -  Objective - improved seeds via biotechnology  R&D and up-front payments - total ~$68M  Crops - corn, soybean, cotton, canola  Milestone payments + royalties from sales  Traits

  35. Slide 35: Disease Resistance Product Candidates

    Slide 35: Disease Resistance Product Candidates

    DISEASE RESISTANCE PRODUCT CANDIDATES* Disease Resistance GMO Product Candidates:* 18m-24m 4-6 year 2-4 year 1-2 years 1-2 years Phase 1 Phase 2 (Early Phase 3 (Adv. Crop Trait Partner Discovery Dev & Phase IV (POC) Development) Product Regulation) (Pre -Launch) Corn Fusarium stalk rot Soybean Asian

  36. Slide 36: Genome Editing Disease Resistance Example

    Slide 36: Genome Editing Disease Resistance Example

    GENOME EDITING DISEASE RESISTANCE EXAMPLE 36

  37. Slide 37: Corporate Structure

    Slide 37: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  38. Slide 38: Biomica - Mission & Products

    Slide 38: Biomica - Mission & Products

    BIOMICA – MISSION & PRODUCTS MISSION Discovery and development of novel therapies for microbiome-related human disorders using computational predictive biology Products under development: Microbiome and small molecule based therapies for:  Immuno-oncology (with ICI) – combination therapy for cancer

  39. Slide 39: Big Biopharma Is Investing More Through Partnerships

    Slide 39: Big Biopharma Is Investing More Through Partnerships

    BIG BIOPHARMA IS INVESTING MORE THROUGH PARTNERSHIPS Obesity and Inflammatory Ulcerative Crohn’s Inflammatory Inflammatory Gastrointestinal metabolic disease bowel disease Colitis disease bowel disease bowel disease indications 2014 2013 2013 2016 2016 2017 2017 Crohn’s Inflammatory Inflammatory Imm

  40. Slide 40: Pipeline

    Slide 40: Pipeline

    PIPELINE Program Indication / Target Discovery Preclinical Phase 1 Phase 2 Approach Combination Therapy BMC121 for NSCLC Immuno- oncology (with ICI) Combination Therapy BMC127 for NSCLC MDRO BMC201 C. difficile toxin-B BMC426 IBS GI related BMC321 IBD disorders BMC322 IBD Biological Small Molecule 4

  41. Slide 41: Corporate Structure

    Slide 41: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  42. Slide 42: Canonic Mission & Products

    Slide 42: Canonic Mission & Products

    CANONIC MISSION & PRODUCTS MISSION To develop and bring to market medical grade cannabis through a revolutionary genomic approach Products under development: Innovative products to address key market needs: ▪ MetaYield* - Increased metabolite yield ▪ Unican* - Verified variety stability ▪ Precise* -

  43. Slide 43: Business Model

    Slide 43: Business Model

    BUSINESS MODEL Canonic aims to develop elite cannabis varieties for commercialization of medical products directly or via partnerships Potential partnerships Varieties dev. Seed production Cannabis growth Formulation Clinical validation & Unique regulation Seeds Flowers varieties 43

  44. Slide 44: Milestone Roadmap

    Slide 44: Milestone Roadmap

    MILESTONE ROADMAP 2019 2020 2021 ➢ Establishment of R&D ➢ First product trait ➢ Finalize development growing facility demonstrated of first improved variety ➢ Complete two ➢ Complete three cannabis growth cycles cannabis growth cycles ➢ Pre-commercial stage ➢ Establish agronomic ➢ Complete ➢ Seed in

  45. Slide 45: Corporate Structure

    Slide 45: Corporate Structure

    CORPORATE STRUCTURE CPB platform Agriculture Human Health Industrial Applications 100% 72% 100% 90% 100% 100% Ag Chemicals Ag Biologicals Seed Traits (division) Human Microbiome Medical Cannabis Castor Oil Herbicides Bio Stimulants (i) Yield, ABST & Human Microbiome High yield, stability Castor Seed

  46. Slide 46: Casterra Mission & Products

    Slide 46: Casterra Mission & Products

    CASTERRA MISSION & PRODUCTS MISSION Providing stable supply for the growing market demand for castor oil Product: An integrated ag-solution for castor - proprietary castor seed varieties supported by novel agro- technical know-how and proprietary mechanical harvesting. Current Practice: Casterra sol

  47. Slide 47: Business Model and Technological Position

    Slide 47: Business Model and Technological Position

    BUSINESS MODEL AND TECHNOLOGICAL POSITION Revenue sharing with oil producers + Partner Partner Variety Seed Grain Oil/Cake Product Breeding technology & Seed production Industrial oil users Grower Crusher genomics Seed sales - Integrated solution (inc. growth protocol & mechanical harvest) Variety S

  48. Slide 48: Pipeline

    Slide 48: Pipeline

    PIPELINE Israel - E1-E2 Target market – D1-D2 Research / Yield trials & Pre-commercial & Commercial Early screening mechanical Harvesting Pre-Breeding Growth Protocol Portfolio 1st generation: CR-712 Compact architecture, adapted to mechanical harvest, uniformity, high germination rate CR-712 2nd ge

  49. Slide 49: Annex II: Financial Fundamentals

    Slide 49: Annex II: Financial Fundamentals

    Annex II: Financial Fundamentals 49

  50. Slide 50: Key Financials – Balance Sheet

    Slide 50: Key Financials – Balance Sheet

    KEY FINANCIALS – BALANCE SHEET Thousand US $ 30.06.2019 31.12.2018 Key Points: Current Assets 47,795 55,488 ▪ Cash position: ~46 million USD as of 30.06.2019 Long-Term Assets 5,659 3,206 ▪ No debt Total Assets 53,454 58,694 ▪ Estimated net cash usage for 2019: $16-$18 million Current Liabilities 4,7

  51. Slide 51: Key Financials – P&L

    Slide 51: Key Financials – P&L

    KEY FINANCIALS – P&L Thousand US $ H1 2019 H1 2018 Q2 2019 Q2 2018 2018 Revenues 540 745 192 379 1,747 Gross Profit 368 196 91 114 295 Operating Loss (9,372) (9,619) (4,703) (4,673) (19,989) Loss (7,895) (10,155) (4,141) (4,769) (20,812) 51

Source: Internet Archive copy of evogene.com

More decks from Evogene Ltd.

All 53 Evogene decks